A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Clinical trial NCT05091528 · TERMINATED

Trial details

NCT number: NCT05091528
Sponsor: Silverback Therapeutics
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer HER2-positive Gastric Cancer HER2-positive Colorectal Cancer HER2-expressing Non-small Cell Lung Cancer

Start date: 2022-02-08
Primary completion: 2022-07-07
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.